Menopausal hormone therapy is associated with worse levels of Alzheimer's disease biomarkers in APOE ε4-carrying women: An observational study.

ABSTRACT:

Introduction

Menopausal hormone therapy (MHT), along with the apolipoprotein E (APOE) ε4 allele, has been suggested as a possible risk factor for Alzheimer's disease (AD). However, the relationship between MHT and cerebrospinal fluid (CSF) biomarkers is unknown: we investigated this association, and whether APOE ε4 carrier status moderates it.

Methods

In an observational study of 136 cognitively unimpaired female participants (M_age = 66.0; standard deviation = 6.3), we examined whether MHT use alone or in interaction with APOE ε4 carrier status was associated with CSF levels of phosphorylated tau (p-tau), amyloid beta (Aβ)40, Aβ42, p-tau/Aβ42, and Aβ42/40 ratios.

Results

Significant interactions were found between APOE ε4 and MHT use for CSF biomarkers. APO

SUBMITTER: Jauregi-Zinkunegi A 

PROVIDER: S-EPMC11848176 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature